4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Krystal Biotech, Inc. (KRYS) operates in the Biotechnology industry and is headquartered in Pittsburgh, United States with about 295 employees. Its market capitalization is roughly $10 billion. In the fiscal year ended 2025-12-31, KRYS reported $389M in revenue and $205M in net income.
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States.
Interactive charts & full statements → Open the KRYS valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $389M | $290M | $51M | $0M | — |
| Gross Profit | $366M | $270M | $48M | $0M | — |
| Operating Income (EBIT) | $161M | $103M | ($97M) | ($120M) | — |
| Net Income | $205M | $89M | $11M | ($140M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $116M | $107M | $98M | $96M | $88M | — |
| Gross Profit | $110M | $100M | $94M | $89M | $83M | — |
| Operating Income (EBIT) | $54M | $44M | $41M | $39M | $36M | — |
| Net Income | $56M | $51M | $79M | $38M | $36M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $1.3B | $1.1B | $818M | $558M | — |
| Total Liabilities | $114M | $110M | $40M | $36M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive KRYS viewer.
About TickerBase · Data methodology & sources